BioMimetic Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

BioMimetic Therapeutics ( BMTI) is a biotechnology company. The company develops and commercializes products to promote the healing of musculoskeletal injuries and diseases, including orthopedic, sports medicine and spine applications. This stock is trading up 8.8% at $2.94 in recent trading.

Today's Range: $2.65-$3.15

52-Week Range: $1.87-$5.59

Volume: 242,000

Three-Month Average Volume: 151,214

>>5 Stocks Under $10 Set to Soar

From a technical perspective, BMTI is skyrocketing here back above its 200-day moving average of $2.66 with heavy volume. This move has now triggered a near-term breakout trade above $2.69 to $2.78, and this stock is flirting with an even bigger breakout trade. That bigger trade will hit once BMTI takes out some past overhead resistance at $3.01 to $3.20 with high-volume. At last check, shares of BMTI have hit an intraday high of $3.15, but it has since pulled back to its current price just under $3.

Traders should now look for long-biased trades if BMTI can sustain a move or close above $3.01 to $3.20 with volume that's near or above 151,214 shares. If we get that action today or soon, look for BMTI to re-test and possibly take out its next significant overhead resistance levels at $3.75 to $4.20.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind